Caprion Announces Biomarker Discovery Collaboration with ICOS

Caprion Pharmaceuticals Inc. has announced additional research collaboration with ICOS Corporation. The agreement in biomarker discovery will use Caprion's CellCarta^® proteomics discovery platform.

Caprion will identify pharmacodynamic markers in plasma relating to ICOS' pre-clinical oncology programs.

"Caprion looks forward to building on the successful tumor antigen target discovery collaboration initiated with ICOS last year with this second collaboration in the area of biomarkers," noted Dr. Daniel Chelsky, Caprion's Chief Scientific Officer.

"We believe that this signals ICOS' confidence in Caprion's ability to discover protein biomarkers that will have a positive impact on their oncology development programs."

Caprion's proprietary proteomics platform is designed to profile the expression and identity of proteins detected in tissues and blood plasma.